Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Core Insights - Assembly Biosciences, Inc. is advancing its antiviral pipeline with four development candidates in clinical studies, with data expected in 2025 [1][2] - The company reported a significant increase in collaborative research revenues and a reduction in net loss compared to the previous year [11][15] Clinical Development - ABI-5366 and ABI-1179 are long-acting helicase-primase inhibitors for recurrent genital herpes, with interim Phase 1b proof-of-concept data expected in fall 2025 [1][4] - ABI-1179 has shown positive Phase 1a interim data, indicating it is well-tolerated and supports potential once-weekly oral dosing [7] - ABI-6250, an oral small molecule entry inhibitor for chronic hepatitis delta virus (HDV), has initiated dosing in Phase 1a studies [7] - ABI-4334, a capsid assembly modulator for chronic hepatitis B virus (HBV), demonstrated a mean decline in HBV DNA of 2.9 log10 IU/mL in a Phase 1b study [7] Financial Performance - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $112.1 million, an increase from $95.0 million as of September 30, 2024 [11] - Revenues from collaborative research rose to $28.5 million in 2024, compared to $7.2 million in 2023, primarily due to a full year of revenue recognition from the collaboration with Gilead [11] - Research and development expenses increased to $55.9 million in 2024 from $48.9 million in 2023, reflecting more candidates in development [11] - The net loss attributable to common stockholders decreased to $40.2 million, or $6.69 per share, from $61.2 million, or $13.38 per share, in 2023 [11][15] Partnerships and Funding - The collaboration with Gilead Sciences resulted in approximately $20.1 million in equity investment and $10 million in accelerated funding to support clinical development programs [7] - The company plans to run concurrent studies for ABI-5366 and ABI-1179, evaluating weekly and monthly oral dosing for recurrent genital herpes [7] Future Milestones - Key upcoming milestones include interim efficacy, safety, and pharmacokinetic data for ABI-5366 and ABI-1179 in fall 2025, and data from ABI-6250 in Q3 2025 [7] - Efficacy, safety, and pharmacokinetic data from the remaining cohort of ABI-4334 is expected in the first half of 2025 [7]